Form 4: Ultragenyx Executive Erik Harris Reports Stock Transactions
SEC Form 4
EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc., Erik Harris, reports acquisition and disposal of company stock and stock options.
Summary
- Erik Harris, EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2024, Harris acquired 19,400 shares of common stock through Restricted Stock Units (RSUs) and 957 shares through the conversion of performance stock units.
- Also on March 1, 2024, Harris sold 4,768 shares at $53.76 to cover tax withholdings related to the vesting of RSUs.
- Harris was also granted stock options for 34,200 shares at an exercise price of $53.69, exercisable starting March 1, 2025.
- Following these transactions, Harris beneficially owns 67,163 shares of common stock and options for 34,200 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. There are no clear positive or negative signals about the company's performance.
Positives
- The grant of RSUs and stock options to an executive can be seen as a positive sign, aligning the executive's interests with those of the shareholders.
- The conversion of performance stock units indicates that performance metrics were met, which is a positive indicator for the company.
Negatives
- The sale of shares to cover tax withholdings, while common, slightly reduces the executive's stake in the company.
Risks
- The vesting of RSUs and stock options is contingent on continued employment and could be forfeited if the executive leaves the company.
- The value of the stock options is dependent on the future performance of the company's stock price.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs and stock options implies a continued relationship between the executive and the company.
Industry Context
Executive stock transactions are common in the pharmaceutical industry as part of compensation packages designed to incentivize performance and align executive interests with shareholder value. These transactions are closely watched by investors for insights into management's confidence in the company's future prospects.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies to attract and retain top talent.
- The vesting schedules and exercise prices are generally in line with industry norms, designed to incentivize long-term value creation.
Stakeholder Impact
- The transactions have a minor impact on shareholders, reflecting changes in executive ownership.
- Employees may be indirectly affected by the executive's incentives to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 10/31/2023 | Acquisition of 293 shares under the Company's Amended & Restated Employee Stock Purchase Plan |
| 03/01/2024 | Date of transaction: Acquisition of RSUs, conversion of performance stock units, and sale of shares for tax withholdings. |
| 03/01/2024 | Grant date of stock options. |
| 03/01/2025 | First vesting date for stock options (1/4th of shares). |
| 03/01/2034 | Expiration date of stock options. |
| 03/05/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.